Brittany Lovely | Authors

Articles

Trastuzumab Deruxtecan Sustains Efficacy Benefit in HER2-Positive mCRC

June 08, 2021

With addition 16-month follow-up, the benefit of fam-trastuzumab deruxtecan-nxki as treatment of patients with HER2-overexpressing metastatic colorectal cancer showed results that were consistent with the primary analysis of the DESTINY-CRC01 trial study.